Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Sep;51(9):1039–1043. doi: 10.1136/ard.51.9.1039

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study.

K P Machold 1, K Neumann 1, J S Smolen 1
PMCID: PMC1004833  PMID: 1417133

Abstract

Interferon gamma (IFN gamma) has been advocated in open studies as a beneficial remission inducing drug for the treatment of rheumatoid arthritis (RA). The work reported here was designed to assess the therapeutic potential of IFN gamma in the treatment of RA in a double blind placebo controlled study. It was found that patients treated with IFN gamma improved significantly with respect to morning stiffness, grip strength, swelling of an index joint, and erythrocyte sedimentation rate. Furthermore significantly more responders (according to predetermined response criteria) were found in the group treated with IFN gamma. Only minor adverse effects and no significant toxicity with respect to clinical or laboratory parameters were observed.

Full text

PDF
1039

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cannon G. W., Pincus S. H., Emkey R. D., Denes A., Cohen S. A., Wolfe F., Saway P. A., Jaffer A. M., Weaver A. L., Cogen L. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1989 Aug;32(8):964–973. doi: 10.1002/anr.1780320805. [DOI] [PubMed] [Google Scholar]
  2. Cavender D., Haskard D., Yu C. L., Iguchi T., Miossec P., Oppenheimer-Marks N., Ziff M. Pathways to chronic inflammation in rheumatoid synovitis. Fed Proc. 1987 Jan;46(1):113–117. [PubMed] [Google Scholar]
  3. Controlled trial of D(-)penicillamine in severe rheumatoid arthritis. Lancet. 1973 Feb 10;1(7798):275–280. [PubMed] [Google Scholar]
  4. FREEDMAN A., STEINBERG V. L. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis. 1960 Sep;19:243–250. doi: 10.1136/ard.19.3.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Felson D. T., Anderson J. J., Meenan R. F. Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum. 1990 Jan;33(1):140–149. doi: 10.1002/art.1780330119. [DOI] [PubMed] [Google Scholar]
  6. Galvani D., Griffiths S. D., Cawley J. C. Interferon for treatment: the dust settles. Br Med J (Clin Res Ed) 1988 Jun 4;296(6636):1554–1556. doi: 10.1136/bmj.296.6636.1554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Janossy G., Panayi G., Duke O., Bofill M., Poulter L. W., Goldstein G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet. 1981 Oct 17;2(8251):839–842. doi: 10.1016/s0140-6736(81)91107-7. [DOI] [PubMed] [Google Scholar]
  8. Kremer J. M., Lee J. K. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986 Jul;29(7):822–831. doi: 10.1002/art.1780290702. [DOI] [PubMed] [Google Scholar]
  9. Lemmel E. M., Brackertz D., Franke M., Gaus W., Hartl P. W., Machalke K., Mielke H., Obert H. J., Peter H. H., Sieper J. Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int. 1988;8(2):87–93. doi: 10.1007/BF00271840. [DOI] [PubMed] [Google Scholar]
  10. Obert H. J., Hofschneider P. H. Interferon bei chronischer Polyarthritis. Positive Wirkung in der klinischen Prüfung. Dtsch Med Wochenschr. 1985 Nov 15;110(46):1766–1769. doi: 10.1055/s-2008-1069083. [DOI] [PubMed] [Google Scholar]
  11. Pinals R. S., Kaplan S. B., Lawson J. G., Hepburn B. Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum. 1986 Dec;29(12):1427–1434. doi: 10.1002/art.1780291202. [DOI] [PubMed] [Google Scholar]
  12. Pinals R. S., Masi A. T., Larsen R. A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981 Oct;24(10):1308–1315. doi: 10.1002/art.1780241012. [DOI] [PubMed] [Google Scholar]
  13. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  14. Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]
  15. Veys E. M., Mielants H., Verbruggen G., Grosclaude J. P., Meyer W., Galazka A., Schindler J. Interferon gamma in rheumatoid arthritis--a double blind study comparing human recombinant interferon gamma with placebo. J Rheumatol. 1988 Apr;15(4):570–574. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES